Trial Profile
Romdomized control study of the effectiveness of pro re nata resume with intra vitreal injection of ranibizumab or aflibercept for polypoidal choroidal vasculopathy
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 19 May 2016
Price :
$35
*
At a glance
- Drugs Aflibercept (Primary) ; Ranibizumab (Primary)
- Indications Polypoidal choroidal vasculopathy
- Focus Therapeutic Use
- 13 May 2015 New trial record